Last reviewed · How we verify

NCT05743543

A Pilot Study of SPG Block for PTSD

Completed EARLY_PHASE1 Last updated 16 February 2024
What this trial tests

EARLY_PHASE1 trial testing Sphenopalatine ganglion block in Post Traumatic Stress Disorder in 6 participants. Completed in 1 June 2023.

Timeline
28 May 2019
Primary endpoint
1 June 2023
1 June 2023

Quick facts

Lead sponsorNew York State Psychiatric Institute
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment6
Start date28 May 2019
Primary completion1 June 2023
Estimated completion1 June 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

New York State Psychiatric Institute

Who can join

Adults 18 to 60, any sex, with Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sphenopalatine ganglion block

Trials testing the same drug.

Other recruiting trials for Post Traumatic Stress Disorder

Currently open trials in the same condition.

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing